Discussion: The role, position, and function of the FDA-The past, present, and future.
作者信息
Fleming Thomas R, Demets David L, McShane Lisa M
机构信息
University of Washington, Seattle, WA, USA.
University of Wisconsin, Madison, WI, USA.
出版信息
Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.
Abstract
摘要
相似文献
1
Discussion: The role, position, and function of the FDA-The past, present, and future.讨论：美国食品药品监督管理局的角色、地位和职能——过去、现在与未来。
Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.
2
Discussion: The FDA is Unprepared for Personalized Medicine.讨论：美国食品药品监督管理局对个性化医疗尚未做好准备。
Biostatistics. 2017 Jul 1;18(3):403-404. doi: 10.1093/biostatistics/kxx018.
3
FDA dependence on drug industry.美国食品药品监督管理局对制药行业的依赖。
J Natl Med Assoc. 2005 Jul;97(7):1039-40.
4
Model-Informed Drug Development: A Regulatory Perspective on Progress.模型引导的药物研发：监管视角下的进展
Clin Pharmacol Ther. 2019 Jul;106(1):91-93. doi: 10.1002/cpt.1475. Epub 2019 Jun 4.
5
6
Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.加速精准医学疗法的证据收集与审批：美国食品药品监督管理局瞄准罕见突变
Genet Med. 2019 Mar;21(3):542-544. doi: 10.1038/s41436-018-0099-0. Epub 2018 Jul 10.
7
The voices of patients and families must be heard.必须倾听患者及其家属的声音。
Epilepsy Behav. 2019 May;94:307. doi: 10.1016/j.yebeh.2019.01.013. Epub 2019 Mar 22.
8
Olestra and the FDA.奥利斯特拉与美国食品药品监督管理局
N Engl J Med. 1996 Apr 11;334(15):984-6. doi: 10.1056/NEJM199604113341511.
9
Financial conflicts of interest and the Food and Drug Administration's Advisory Committees.经济利益冲突与美国食品药品监督管理局咨询委员会
N Engl J Med. 2005 Jul 14;353(2):116-8. doi: 10.1056/NEJMp058108.
10
Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees.美国食品药品监督管理局药物咨询委员会患者及消费者代表的利益冲突
Ann Intern Med. 2016 Oct 18;165(8):606-607. doi: 10.7326/L16-0031.
引用本文的文献
1
Reforming Food, Drug, and Nutraceutical Regulations to Improve Public Health and Reduce Healthcare Costs.改革食品、药品和营养保健品监管制度以改善公众健康并降低医疗成本。
Foods. 2025 Jun 30;14(13):2328. doi: 10.3390/foods14132328.
2
Primum non nocere: Toward a Greater Understanding of the Potential for Harm in Psychological Treatments for Youth.首要的是不伤害：增进对青少年心理治疗中潜在伤害的理解。
Res Child Adolesc Psychopathol. 2025 May;53(5):597-607. doi: 10.1007/s10802-025-01323-z. Epub 2025 Apr 30.
3
Nanomedicine Therapies for Pediatric Diseases.儿科疾病的纳米医学疗法。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e1996. doi: 10.1002/wnan.1996.
4
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023.美国食品药品监督管理局（FDA）2023年生物药品批准情况
Biomedicines. 2024 Sep 2;12(9):1992. doi: 10.3390/biomedicines12091992.
本文引用的文献
1
Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.美国食品药品监督管理局的获益-风险评估：寻求平衡
JAMA. 2017 Feb 21;317(7):693-694. doi: 10.1001/jama.2017.0410.
2
Clinical trials: discerning hype from substance.临床试验：甄别炒作与实质。
Ann Intern Med. 2010 Sep 21;153(6):400-6. doi: 10.7326/0003-4819-153-6-201009210-00008.
3
Sensible approaches for reducing clinical trial costs.降低临床试验成本的合理方法。
Clin Trials. 2008;5(1):75-84. doi: 10.1177/1740774507087551.
Zotero 插件